The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
 
Erika Paige Hamilton
No Relationships to Disclose
 
Denise A. Yardley
No Relationships to Disclose
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Amgen; Antigen Express; Galena Biopharma; Genentech; Novartis; Peregrine Pharmaceuticals; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Luke N. Walker
Employment - Oncothyreon
Stock and Other Ownership Interests - Oncothyreon
 
Virginia F. Borges
No Relationships to Disclose
 
Stacy L. Moulder
No Relationships to Disclose